Put this in the category of good problems to have: In its first four years on the market, Keytruda, made by Merck, has had the best sales launch in the history of cancer drugs.

In the third quarter of 2018, Merck reported sales of $1.9 billion of the checkpoint inhibitor, 18 percent of the company’s total revenue. Keytruda sales have now surpassed those of Opdivo, a similar medicine from Bristol-Myers Squibb. According to projections collected by Evaluate Pharma and touted by Merck, full-year sales of Keytruda will approach $7 billion.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • What pains me even more is they are saying their revenue by 2020 will be like 16 billion fda released a warning to doctors in 2017 asking to stop the trials but I suppose money talks

  • Well this drug actually killed my mother caused a disease that is called myanstinious gravis and paralyzed her so yeah it does pain me to read this article

  • I am not impressed with the knowledge that your company made so much money for a drug that is supposed to help people with a serious disease as Cancer is. This drug did NOT do my son any good after 11 months but cause him alot of side effects . It’s a shame that you are able to brag about the money made from this. Unbelievable!!!

  • “To much on one drug,” Matthew? Compared to AbbVee and the former Celgene, that’s not so much of a concentration, is it? (Enjoy the rest of JPM!)

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy